Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057323 | 0.85 | MAPT (0.44) | ALDH1A1MAPTHTTHPGDKDM4E | |
| SCHEMBL4056575 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTHTTHPGDKMT2A | |
| SCHEMBL4055917 | 0.78 | KMT2A (0.56) | KMT2A | |
| SCHEMBL5343442 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTHTTHPGDKDM4E | |
| SCHEMBL4061232 | 0.77 | ALDH1A1 (0.45) | ALDH1A1MAPTHTTHPGDKMT2A | |
| SCHEMBL4056791 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTHTTKMT2AMEN1 | |
| SCHEMBL4059076 | 0.74 | SIGMAR1 (0.43) | ALDH1A1MAPTHTTHPGDKMT2A | |
| SCHEMBL30079692 | 0.74 | MAPT (0.75) | ALDH1A1MAPTHTTKMT2AMEN1 | |
| SCHEMBL2822088 | 0.74 | MAPT (0.75) | ALDH1A1MAPTHTTKMT2AMEN1 | |
| SCHEMBL5318002 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HTTHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | claimed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | claimed |
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | ALDH1A1 3097/4885MAPT 1326/4885HTT 1407/4885 |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | CYP1B1, TPMT, CYP7B1 | ALDH1A1 112/4885MAPT 2515/4885HTT 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.